HIV, alcohol dependence, and the criminal justice system: a review and call for evidence-based treatment for released prisoners

References

• The Pew Center on the States. One in 100: Behind Bars in America. Washington, DC: The Pew Charitable Trusts, Feb 28, 2008.
   Google Scholar
• Hammett TM, Harmon MP, Rhodes W. The burden of infectious disease among inmates of and releasees from US correctional facilities, 1997. Am J Public Health 2002; 92(11): 1789–1794.
   PubMed Web of Science ®Google Scholar
• Maruschak L, Beavers R. HIV in Prisons, 2007–08. Washington, DC: US Department of Justice, Office of Justice Programs, 2009.
   Google Scholar
• Spaulding AC, Seals RM, Page MJ, Brzozowski AK, Rhodes W, Hammett TM. HIV/AIDS among inmates of and releasees from US correctional facilities, 2006: Declining share of epidemic but persistent public health opportunity. PLoS ONE 2009; 4(11):e7558.
   PubMed Web of Science ®Google Scholar
• Springer SA, Pesanti E, Hodges J, Macura T, Doros G, Altice FL. Effectiveness of antiretroviral therapy among HIV-infected prisoners: Reincarceration and the lack of sustained benefit after release to the community. Clin Infect Dis 2004; 38(12):1754–1760.
   PubMed Web of Science ®Google Scholar
• Stephenson BL, Wohl DA, Golin CE, Tien HC, Stewart P, Kaplan AH. Effect of release from prison and re-incarceration on the viral loads of HIV-infected individuals. Public Health Rep Jan–Feb 2005; 120(1):84–88.
   Google Scholar
• Centers for Disease Control (CDC). Decrease in AIDS-related mortality in a state correctional system – New York, 1995–1998. MMWR Morb Mortal Wkly Rep Jan 8 1999; 47(51–52):1115–1117.
   PubMedGoogle Scholar
• Springer S, Altice F. Improving the care for HIV-infected prisoners: An integrated prison-release health model. In Public Health Behind Bars: From Prisons to Communities. Greifinger R, ed. New York, NY: Springer Science, 2007.
   Google Scholar
• Kinlock TW, Battjes RJ, Schwartz RP. A novel opioid maintenance program for prisoners: Preliminary findings. J Subst Abuse Treat 2002; 22(3):141–147.
   PubMed Web of Science ®Google Scholar
• Levasseur L, Marzo J, Ross N, Blatier C. Frequency of re-incarcerations in the same detention center: Role of substitution therapy. A preliminary retrospective analysis. Ann Med Interne 2002; 153(3 Suppl):1S14–1S19.
   Google Scholar
• Peters RH, Greenbaum PE, Edens JF, Carter CR, Ortiz MM. Prevalence of DSM-IV substance abuse and dependence disorders among prison inmates. Am J Drug Alcohol Abuse Nov 1998; 24(4):573–587.
   PubMed Web of Science ®Google Scholar
• Chandler RK, Fletcher BW, Volkow ND. Treating drug abuse and addiction in the criminal justice system: Improving public health and safety. JAMA Jan 14 2009; 301(2):183–190.
   PubMed Web of Science ®Google Scholar
• Baillargeon J, Giordano TP, Rich JD, Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM, Singh N. Accessing antiretroviral therapy following release from prison. JAMA Feb 25 2009; 301(8):848–857.
   PubMed Web of Science ®Google Scholar
• Altice F, Khoshnood K. Transitional Case Management as a Strategy for Linking HIV-Infected Prisoners to Community Health and Social Services ( Project TLC). Connecticut Department of Public Heath Monograph, 1997.
   Google Scholar
• Karberg J, James D. Substance Dependence, Abuse, and Treatment of Jail Inmates, 2002. Washington, DC, 2005; NCJ 209588.
   Google Scholar
• Binswanger IA, Stern MF, Deyo RA, Release from prison – A high risk of death for former inmates. N Engl J Med 2007; 356(2):157–165.
   PubMed Web of Science ®Google Scholar
• Smith-Rohrberg D, Bruce RD, Altice FL. Review of corrections-based therapy for opiate-dependent patients: Implications for buprenorphine treatment among correctional populations. J Drug Issues 2004; 34(2):451–480.
   Google Scholar
• Sabol WJ, Couture H, & Harrison PM. (2007). Prisoners in 2006. Bureau of Justice Statistics. Bulletin. Retrieved August 14, 2008 from: http://www.ojp.gov/bjs/pub/pdf/p06.pdf
   Google Scholar
• Mumola C. Substance Abuse and Treatment, State and Federal Prisoners, 1997. Washington, DC: US Department of Justice, Bureau of Justice Statistics, 1999; 1–16.
   Google Scholar
• National Center on Addiction and Substance Abuse (CASA). Addiction treatment in prison will reduce crime, save billions of tax dollars, says CASA report. News Briefs, 1998. Available at www.ndsn.org/jan98/prisons1.html. Last accessed on March 28, 2005.
   Google Scholar
• Testino G. Alcoholic diseases in hepato-gastroenterology: A point of view. Hepatogastroenterology Mar–Apr 2008; 55(82–83):371–377.
   PubMedGoogle Scholar
• Volpicelli JR. Alcohol abuse and alcoholism: An overview. J Clin Psychiatrys 2001; 62 (Suppl 20):4–10.
   PubMed Web of Science ®Google Scholar
• Caan W. Drink, Drugs and Dependence: From Science to Clinical Practice. (1st ed.). London: Routledge, 2002.
   Google Scholar
• Fazel S, Bains P, Doll H. Substance abuse and dependence in prisoners: A systematic review. Addiction Feb 2006; 101(2):181–191.
   PubMed Web of Science ®Google Scholar
• Shuper PA, Joharchi N, Irving H, Rehm J. Alcohol as a correlate of unprotected sexual behavior among people living with HIV/AIDS: Review and meta-analysis. AIDS Behav Dec 2009; 13(6):1021–1036.
   PubMed Web of Science ®Google Scholar
• Woolf SE, Maisto SA. Alcohol use and risk of HIV infection among men who have sex with men. AIDS Behav Aug 2009; 13(4):757–782.
   PubMed Web of Science ®Google Scholar
• Hendershot CS, Stoner SA, Pantalone DW, Simoni JM. Alcohol use and antiretroviral adherence: Review and meta-analysis. J Acquir Immune Defic Syndr Oct 1 2009; 52:180–202.
   PubMed Web of Science ®Google Scholar
• Zarkin GA, Bray JW, Babor TF, Higgins-Biddle JC. Alcohol drinking patterns and health care utilization in a managed care organization. Health Serv Res Jun 2004; 39(3):553–570.
   PubMed Web of Science ®Google Scholar
• Green JE, Saveanu RV, Bornstein RA. The effect of previous alcohol abuse on cognitive function in HIV infection. Am J Psychiatry Feb 2004; 161(2):249–254.
   PubMed Web of Science ®Google Scholar
• RachBeisel J, Scott J, Dixon L. Co-occurring severe mental illness and substance use disorders: A review of recent research. Psychiatr Serv Nov 1999; 50(11):1427–1434.
   PubMed Web of Science ®Google Scholar
• Smith-Rohrberg Maru D, Basu S, Altice FL. HIV control efforts should directly address incarceration. Lancet Infect Dis 2007; 7(9):568–569.
   PubMed Web of Science ®Google Scholar
• Linder JF, Enders SR, Craig E, Richardson J, Meyers FJ. Hospice care for the incarcerated in the United States: An introduction. J Palliat Med Aug 2002; 5(4):549–552.
   PubMedGoogle Scholar
• Murphy EL, Collier AC, Kalish LA, Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med Jul 3 2001; 135(1):17–26.
   PubMed Web of Science ®Google Scholar
• Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM, Singh N. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med Jul 4 2000; 133(1):21–30.
   PubMed Web of Science ®Google Scholar
• Springer SA, Friedland GH, Doros G, Pesanti E, Altice FL. Antiretroviral treatment regimen outcomes among HIV-infected prisoners. HIV Clin Trials 2007; 8(4):205–212.
   PubMed Web of Science ®Google Scholar
• Baillargeon J, Borucki MJ, Zepeda S, Jenson HB, Leach CT. Antiretroviral prescribing patterns in the Texas prison system. Clin Infect Dis Dec 2000; 31(6):1476–1481.
   PubMed Web of Science ®Google Scholar
• Stephenson BL, Wohl DA, McKaig R, Sexual behaviours of HIV-seropositive men and women following release from prison. Int J STD AIDS Feb 2006; 17(2):103–108.
   PubMed Web of Science ®Google Scholar
• Estebanez P, Zunzunegui MV, Aguilar MD, Russell N, Cifuentes I, Hankins C. The role of prisons in the HIV epidemic among female injecting drug users. AIDS Care Feb 2002; 14(1):95–104.
   PubMed Web of Science ®Google Scholar
• Tyndall MW, Patrick D, Spittal P, Li K, O'Shaughnessy MV, Schechter MT. Risky sexual behaviours among injection drugs users with high HIV prevalence: Implications for STD control. Sex Transm Infect 2002; 78(Suppl 1):i170–i175.
   PubMed Web of Science ®Google Scholar
• Margolis AD, MacGowan RJ, Grinstead O, Sosman J, Kashif I, Flanigan TP. Unprotected sex with multiple partners: Implications for HIV prevention among young men with a history of incarceration. Sex Transm Dis 2006; 33(3):175–180.
   PubMed Web of Science ®Google Scholar
• Safren SA, Wingood G, Altice FL. Strategies for primary HIV prevention that target behavioral change. Clin Infect Dis Dec 15 2007; 45 (Suppl 4):S300–S307.
   PubMed Web of Science ®Google Scholar
• Weaver MR, Conover CJ, Proescholdbell RJ, Arno PS, Ang A, Ettner SL. Utilization of mental health and substance abuse care for people living with HIV/AIDS, chronic mental illness, and substance abuse disorders. J Acquir Immune Defic Syndr Apr 1 2008; 47(4):449–458.
   PubMed Web of Science ®Google Scholar
• Cunningham CO, Sohler NL, Wong MD, Utilization of health care services in hard-to-reach marginalized HIV-infected individuals. AIDS Patient Care STDS Mar 2007; 21(3):177–186.
   PubMed Web of Science ®Google Scholar
• Malow RM, Baker SM, Klimas N, Adherence to complex combination antiretroviral therapies by HIV-positive drug abusers. Psychiatr Serv Aug 1998; 49(8):1021–1022, 1024.
   PubMed Web of Science ®Google Scholar
• Mellins CA, Havens JF, McDonnell C, Adherence to antiretroviral medications and medical care in HIV-infected adults diagnosed with mental and substance abuse disorders. AIDS Care Feb 2009; 21(2):168–177.
   PubMed Web of Science ®Google Scholar
• Lucas GM, Gebo KA, Chaisson RE, Moore RD. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS 2002; 16(5): 767–774.
   PubMed Web of Science ®Google Scholar
• Theall K, Clark R, Powell A, Smith H, Kissinger P. Alcohol consumption, art usage and high-risk sex among women infected with HIV. AIDS Behav 2007; 11:205–215.
   PubMed Web of Science ®Google Scholar
• Palepu A, Tyndall MW, Li K, Alcohol use and incarceration adversely affect HIV-1 RNA suppression among injection drug users starting antiretroviral therapy. J Urban Health Dec 2003; 80(4):667–675.
   PubMed Web of Science ®Google Scholar
• Soriano V, Puoti M, Sulkowski M, Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007; 21(9):1073–1089.
   PubMed Web of Science ®Google Scholar
• Serfaty L, Poujol-Robert A, Carbonell N, Chazouilleres O, Poupon RE, Poupon R. Effect of the interaction between steatosis and alcohol intake on liver fibrosis progression in chronic hepatitis C. Am J Gastroenterol Jul 2002; 97(7):1807–1812.
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Host- and disease-specific factors affecting steatosis in chronic hepatitis C. J Hepatol 1998; 29(2):198–206.
   PubMed Web of Science ®Google Scholar
• Salmon-Ceron D, Lewden C, Morlat P, Liver disease as a major cause of death among HIV infected patients: Role of hepatitis C and B viruses and alcohol. J Hepatol Jun 2005; 42(6):799–805.
   PubMed Web of Science ®Google Scholar
• Weber R, Sabin CA, Friis-Moller N, Liver-related deaths in persons infected with the human immunodeficiency virus: The D:A:D study. Arch Intern Med 2006; 166(15): 1632–1641.
   PubMed Web of Science ®Google Scholar
• Peters R, Wexler H, Tip 44: Substance Abuse Treatment for Adults in the Criminal Justice System. Rockville, MD: United States Department of Health and Human Services (DHHS), 2008.
   Google Scholar
• Volpicelli J, Pettinati H, McLellan A, O'Brien C. Combining Medication and Psychosocial Treatments for Addictions: The BRENDA Approach. New York, NY: Guilford Press, 2001.
   Google Scholar
• Pettinati H, Weiss R, Miller WR, Donovan D, Ernst D, Rounsaville BJ. Medical Management Treatment Providing Pharmacotherapy as Part of the Treatment for Alcohol Dependence. DHHS Publication No. (NIH) 04–5289. Bethesda, MD: NIAAA, 2004. http://www.thomsonhc.com/hcs/librarian/ND_T/HCS/ND_PR/Main/CS/9C5A7A/DUPLICATIONSHIELDSYNC/3D3248/ND_PG/PRIH/ND_B/HCS/SBK/3/ND_P/Main/PFActionId/hcs.common.RetrieveDocumentCommon/DocId/184770/ContentSetId/100/SearchTerm/disulfiram/SearchOption/BeginWith
   Google Scholar
• Monterosso JR, Flannery BA, Pettinati HM, Predicting treatment response to naltrexone: The influence of craving and family history. Am J Addict. Summer 2001; 10(3):258–268.
   PubMed Web of Science ®Google Scholar
• Oslin DW, Lynch KG, Pettinati HM, A placebo-controlled randomized clinical trial of naltrexone in the context of different levels of psychosocial intervention. Alcohol Clin Exp Res 2008; 32(7):1299–1308.
   PubMed Web of Science ®Google Scholar
• Kadden R, Carrol K, Donovan D, Cognitive Behavioral Coping Skills Therapy Manual: A Clinical Research Guide for Therapists Treating Individuals with Alcohol Abuse and Dependence. NIH Publication No. Rockville, MD: National Institute on Alcohol Abuse and Alcoholism, 1995:94–3724.
   Google Scholar
• Anton RF, Moak DH, Waid LR, Latham PK, Malcolm RJ, Dias JK. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: Results of a placebo-controlled trial. Am J Psychiatry 1999; 156(11):1758–1764.
   PubMed Web of Science ®Google Scholar
• Anton RF. New methodologies for pharmacological treatment trials for alcohol dependence. Alcohol Clin Exp Res 1996; 20(7 Suppl):3A–9A.
   PubMed Web of Science ®Google Scholar
• Cullen F, Gendreau P. The effectiveness of correctional rehabilitation: Reconsidering the “nothing works” debate. Goodstein L, MacKenzie D, eds. In The American Prison: Issues in Research and Policy. New York, NY: Plenum Press, 1989; 23–44.
   Google Scholar
• Whitlock EP, Polen MR, Green CA, Orleans T, Klein J. Behavioral counseling interventions in primary care to reduce risky/harmful alcohol use by adults: A summary of the evidence for the US Preventive Services Task Force. Ann Intern Med. Apr 6 2004; 140(7):557–568.
   PubMed Web of Science ®Google Scholar
• Palepu A, Horton NJ, Tibbetts N, Meli S, Samet JH. Uptake and adherence to highly active antiretroviral therapy among HIV-infected people with alcohol and other substance use problems: The impact of substance abuse treatment. Addiction Mar 2004; 99(3):361–368.
   PubMed Web of Science ®Google Scholar
• Suh JJ, Pettinati HM, Kampman KM, O'Brien CP. The status of disulfiram: A half of a century later. J Clin Psychopharmacol Jun 2006; 26(3):290–302.
   PubMed Web of Science ®Google Scholar
• DIsulfiram. Thomson MICROMEDEX,; 2006. Available at http://www.thomsonhc.com/hcs/librarian/ND_T/HCS/ND_PR/Main/CS/9C5A7A/DUPLICATIONSHIELDSYNC/3D3248/ND_PG/PRIH/ND_B/HCS/SBK/3/ND_P/Main/PFActionId/hcs.common.RetrieveDocumentCommon/DocId/184770/ContentSetId/100/SearchTerm/disulfiram/SearchOption/BeginWith. Last accessed November 29, 2006.
   Google Scholar
• Kranzler HR, Rounsaville BJ. Dual Diagnosis and Treatment: Substance Abuse and Comorbid Medical and Psychiatric Disorders. New York, NY: Marcel Dekker, 1998.
   Google Scholar
• Rush BR, Malla A. A comparison of disulfiram acceptors and refusers on selected demographic and clinical characteristics. Drug Alcohol Depend Sep 1984; 14(1):75–85.
   PubMed Web of Science ®Google Scholar
• Bourne PG, Alford JA, Bowcock JZ. Treatment of skid-row alcoholics with disulfiram. Q J Stud Alcohol Mar 1966; 27(1):42–48.
   PubMedGoogle Scholar
• Haynes SN. Contingency management in a municipally-administered antabuse program for alcoholics. J Behav Ther Exp Psychiatry 1973; 4(1):31.
   Web of Science ®Google Scholar
• Sereny G, Sharma V, Holt J, Gordis E. Mandatory supervised antabuse therapy in an outpatient alcoholism program: A pilot study. Alcohol Clin Exp Res Jun 1986; 10(3):290–292.
   PubMed Web of Science ®Google Scholar
• Gallant DM, Bishop MP, Faulkner MA, A comparative evaluation of compulsory (group therapy and-or antabuse) and voluntary treatment of the chronic alcoholic municipal court offender. Psychosomatics. Nov–Dec 1968; 9(6):306–310.
   PubMed Web of Science ®Google Scholar
• Acamprosate. Thomson MICROMEDEX, 2006. Available at http://www.thomsonhc.com/hcs/librarian/ND_T/HCS/ND_PR/Main/CS/9C5A7A/DUPLICATIONSHIELDSYNC/3D3248/ND_PG/PRIH/ND_B/HCS/SBK/6/ND_P/Main/PFActionId/hcs.common.RetrieveDocumentCommon/ DocId/928307/ContentSetId/100/SearchTerm/acamprosate/ SearchOption/BeginWith. Last accessed November 29, 2006.
   Google Scholar
• Littleton J. Acamprosate in alcohol dependence: How does it work? Addiction Sep 1995; 90(9):1179–1188.
   PubMed Web of Science ®Google Scholar
• Mason BJ, Goodman AM, Dixon RM, A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone. Neuropsychopharmacology Oct 2002; 27(4):596–606.
   PubMed Web of Science ®Google Scholar
• Mason BJ. Treatment of alcohol-dependent outpatients with acamprosate: A clinical review. J Clin Psychiatry 2001; 62 (Suppl 20):42–48.
   PubMed Web of Science ®Google Scholar
• Krupitsky EM, Zvartau EE, Lioznov DA, Co-morbidity of infectious and addictive diseases in St. Petersburg and the Leningrad Region, Russia. Eur Addict Res 2006; 12(1): 12–19.
   PubMed Web of Science ®Google Scholar
• Project MATCH Research Group. Matching Alcoholism Treatments to Client Heterogeneity: Project MATCH posttreatment drinking outcomes. J Stud Alcohol Jan 1997; 58(1):7–29.
   PubMed Web of Science ®Google Scholar
• O'Malley SS. Opioid antagonists in the treatment of alcohol dependence: Clinical efficacy and prevention of relapse. Alcohol 1996; 31(Suppl 1):77–81.
   Google Scholar
• O'Malley SS, Froehlich JC. Advances in the use of naltrexone: An integration of preclinical and clinical findings. Recent Dev Alcohol 2003; 16:217–245.
   PubMedGoogle Scholar
• O'Brien CP. Anticraving medications for relapse prevention: A possible new class of psychoactive medications. Am J Psychiatry Aug 2005; 162(8):1423–1431.
   PubMed Web of Science ®Google Scholar
• Gianoulakis C, Krishnan B, Thavundayil J. Enhanced sensitivity of pituitary beta-endorphin to ethanol in subjects at high risk of alcoholism [erratum appears in Arch Gen Psychiatry 1996 Jun; 53(6):555]. Arch Gen Psychiatry Mar 1996; 53(3):250–257.
   PubMed Web of Science ®Google Scholar
• Balldin J, Berglund M, Borg S, A 6-month controlled naltrexone study: Combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence. Alcohol Clin Exp Res Jul 2003; 27(7):1142–1149.
   PubMed Web of Science ®Google Scholar
• Monterosso JR, Flannery BA, Pettinati HM, Predicting treatment response to naltrexone: The influence of craving and family history. Am J Addict 2001; 10(3):258–268.
   PubMed Web of Science ®Google Scholar
• Petrakis IL, Poling J, Levinson C, Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders. Biol Psychiatry May 15 2005; 57(10):1128–1137.
   PubMed Web of Science ®Google Scholar
• Garbutt JC, Kranzler HR, O'Malley SS, Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: A randomized controlled trial. JAMA Apr 6 2005; 293(13):1617–1625.
   PubMed Web of Science ®Google Scholar
• Bruce RD, Altice FL, Gourevitch MN, Friedland GH. Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: Implications andmanagement for clinical practice. J Acquir Immune Defic Syndr Apr 15 2006; 41(5):563–572.
   PubMed Web of Science ®Google Scholar
• Alkermes Pharmaceuticals. VIVITROL™ Package Insert, 2006; http://129.128.185.122/drugbank2/drugs/DB00704/fda_labels/153. Last accessed January 4, 2010.
   Google Scholar
• Jeffrey GP, MacQuillan G, Chua F, Hepatitis C virus eradication in intravenous drug users maintained with subcutaneous naltrexone implants. Hepatology Jan 2007; 45(1): 111–117.
   PubMed Web of Science ®Google Scholar
• Weinrieb RM, O'Brien CP. A case report of naltrexone for alcoholism in a liver transplant recipient: Side effects and safety. Am J Addict Oct–Dec 2004; 13(5):495–497.
   PubMed Web of Science ®Google Scholar
• Weinrieb RM, Van Horn DH, McLellan AT, Alcoholism treatment after liver transplantation: Lessons learned from a clinical trial that failed. Psychosomatics Mar–Apr 2001; 42(2):110–116.
   PubMed Web of Science ®Google Scholar
• Wolfhagen FH, Sternieri E, Hop WC, Vitale G, Bertolotti M, Van Buuren HR. Oral naltrexone treatment for cholestatic pruritus: A double-blind, placebo-controlled study. Gastroenterology Oct 1997; 113(4):1264–1269.
   PubMed Web of Science ®Google Scholar
• Nunn A, Zaller N, Dickman S, Trimbur C, Nijhawan A, Rich JD. Methadone and buprenorphine prescribing and referral practices in US prison systems: Results from a nationwide survey. Drug Alcohol Depend 2009; 105(1–2):83–88.
   PubMed Web of Science ®Google Scholar
• Perez LM, Ro MJ, Treadwell HM. Vulnerable populations, prison, and federal and state Medicaid policies: Avoiding the loss of a right to care. J Correct Health Care Apr 2009; 15(2):142–149.
   PubMedGoogle Scholar
• National Center on Addiction and Substance Abuse (CASA). Behind Bars: Substance Abuse and America's Prison Population. New York, NY: Columbia University, 1998.
   Google Scholar
• American Correctional Association. Standards for Adult Correctional Institutions. (3rd ed.). Lanham, MD: American Correctional Association, 1990.
   Google Scholar
• Center for Substance Abuse Treatment. Substance Abuse Treatment for Adults in the Criminal Justice System. Treatment Improvement Protocol (TIP) Series 44. DHHS Publication No. (SMA) 05–4056. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2005.
   Google Scholar
• Peters R, Steinberg M. Substance abuse treatment services in US prisons. Shewan D, Davies J, eds. In Drug Use and Prisons. Singapore: Harwood Academic Publishers, 2000;89–116.
   Google Scholar
• Copenhaver M, Chowdhury S, Altice FL. Adaptation of an evidence-based intervention targeting HIV-infected prisoners transitioning to the community: The process and outcome of formative research for the positive living using safety (PLUS) intervention. AIDS Patient Care STDS Apr 2009; 23(4): 277–287.
   PubMed Web of Science ®Google Scholar
• Grinstead O, Zack B, Faigeles B. Reducing postrelease risk behavior among HIV seropositive prison inmates: The health promotion program. AIDS Educ Prev Apr 2001; 13(2): 109–119.
   PubMed Web of Science ®Google Scholar
• Springer S, Chen S, Altice FL. Improved HIV and substance abuse treatment outcomes for released HIV-infected prisoners: The impact of buprenorphine treatment. J Urban Health 2010; 87(4):592–602.
   PubMed Web of Science ®Google Scholar
• Krupitzky E, Illeperuma A, Gastfriend DR, Silverman BL. Efficacy and Safety of Extended-Release Injectable Naltrexone (XR-NTX) for the Treatment of Opioid Dependence. New Orleans, LA: American Psychiatric Association, 2010.
   Google Scholar
• Wohl DA, Scheyett A, Golin CE, White B, Matuszewski J, Bowling M, Smith P, Duffin F, Rosen D, Kaplan A, Earp J. Intensive Case Management Before and After Prison Release is No More Effective Than Comprehensive Pre-Release Discharge Planning in Linking HIV-Infected Prisoners to Care: A Randomized Trial. AIDS Behav. In Press, 2010:
   Google Scholar